Actively Recruiting
Rezdiffra Pregnancy and Lactation Registry
Led by Madrigal Pharmaceuticals, Inc. · Updated on 2026-04-21
10
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
CONDITIONS
Official Title
Rezdiffra Pregnancy and Lactation Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients with NASH who have been exposed to at least 1 dose of resmetirom at any time during pregnancy (within 3 days prior to conception and/or during pregnancy) and/or during lactation, and their infants up to 12 months of age
- Ability to understand and provide informed consent or assent through an approved consent form
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Madrigal Pharmaceuticals
West Conshohocken, Pennsylvania, United States, 19428
Actively Recruiting
Research Team
M
Madrigal Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here